3oyp: Difference between revisions
From Proteopedia
Jump to navigationJump to search
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
[[ | ==HCV NS3/4A in complex with ligand 3== | ||
<StructureSection load='3oyp' size='340' side='right' caption='[[3oyp]], [[Resolution|resolution]] 2.76Å' scene=''> | |||
== Structural highlights == | |||
<table><tr><td colspan='2'>[[3oyp]] is a 6 chain structure with sequence from [http://en.wikipedia.org/wiki/Hepatitis_c_virus_(isolate_japanese) Hepatitis c virus (isolate japanese)]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3OYP OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=3OYP FirstGlance]. <br> | |||
</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=ZN:ZINC+ION'>ZN</scene></td></tr> | |||
<tr id='NonStdRes'><td class="sblockLbl"><b>[[Non-Standard_Residue|NonStd Res:]]</b></td><td class="sblockDat"><scene name='pdbligand=0Y8:(4R)-4-[(7-BROMOISOQUINOLIN-1-YL)OXY]-L-PROLINE'>0Y8</scene>, <scene name='pdbligand=0Y9:(1R,2S)-1-AMINO-2-ETHENYLCYCLOPROPANECARBOXYLIC+ACID'>0Y9</scene>, <scene name='pdbligand=0YA:CYCLOPROPANESULFONAMIDE'>0YA</scene>, <scene name='pdbligand=DAL:D-ALANINE'>DAL</scene>, <scene name='pdbligand=PPI:PROPANOIC+ACID'>PPI</scene></td></tr> | |||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=3oyp FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=3oyp OCA], [http://www.rcsb.org/pdb/explore.do?structureId=3oyp RCSB], [http://www.ebi.ac.uk/pdbsum/3oyp PDBsum]</span></td></tr> | |||
</table> | |||
<div style="background-color:#fffaf0;"> | |||
== Publication Abstract from PubMed == | |||
Designing selective inhibitors of proteases has proven problematic, in part because pharmacophores that confer potency exploit the conserved catalytic apparatus. We developed a fundamentally different approach by designing irreversible inhibitors that target noncatalytic cysteines that are structurally unique to a target in a protein family. We have successfully applied this approach to the important therapeutic target HCV protease, which has broad implications for the design of other selective protease inhibitors. | |||
Selective irreversible inhibition of a protease by targeting a noncatalytic cysteine.,Hagel M, Niu D, St Martin T, Sheets MP, Qiao L, Bernard H, Karp RM, Zhu Z, Labenski MT, Chaturvedi P, Nacht M, Westlin WF, Petter RC, Singh J Nat Chem Biol. 2011 Jan;7(1):22-4. Epub 2010 Nov 28. PMID:21113170<ref>PMID:21113170</ref> | |||
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | |||
</div> | |||
== References == | |||
<references/> | |||
__TOC__ | |||
</StructureSection> | |||
[[Category: Bernard, H]] | |||
== | [[Category: Chaturvedi, P C]] | ||
< | [[Category: Hagel, M]] | ||
[[Category: Bernard, H | [[Category: Karp, R M]] | ||
[[Category: Chaturvedi, P C | [[Category: Labenski, M T]] | ||
[[Category: Hagel, M | [[Category: Martin, T St]] | ||
[[Category: Karp, R M | [[Category: Nacht, M]] | ||
[[Category: Labenski, M T | [[Category: Niu, D]] | ||
[[Category: Martin, T St | [[Category: Petter, R C]] | ||
[[Category: Nacht, M | [[Category: Qiao, L]] | ||
[[Category: Niu, D | [[Category: Sheets, M P]] | ||
[[Category: Petter, R C | [[Category: Singh, J]] | ||
[[Category: Qiao, L | [[Category: Westlin, W F]] | ||
[[Category: Sheets, M P | [[Category: Zhu, Z]] | ||
[[Category: Singh, J | |||
[[Category: Westlin, W F | |||
[[Category: Zhu, Z | |||
[[Category: Hepatitis c virus]] | [[Category: Hepatitis c virus]] | ||
[[Category: Hydrolase-hydrolase inhibitor complex]] | [[Category: Hydrolase-hydrolase inhibitor complex]] | ||
Revision as of 12:14, 9 December 2014
HCV NS3/4A in complex with ligand 3
| ||||||||||||
